Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company dedicated to creating another future for people suffering from neurodegenerative diseases. The company's lead product, ATH434, has the potential to treat various forms of Parkinson's disease. Alterity also owns an extensive drug discovery platform capable of generating patentable chemical compounds to intervene in disease processes. The company’s scientific focus is on neurological disorders, particularly Alzheimer's, Parkinson's, and Huntington's diseases.